Factors affecting hesitancy toward COVID-19 vaccine booster doses in Canada: a cross-national survey
-
Published:2023-11-22
Issue:
Volume:
Page:
-
ISSN:0008-4263
-
Container-title:Canadian Journal of Public Health
-
language:en
-
Short-container-title:Can J Public Health
Author:
Leigh Jeanna ParsonsORCID, FitzGerald Emily A., Moss Stephana J., Brundin-Mather Rebecca, Dodds Alexandra, Stelfox Henry T., Dubé Ève, Fiest Kirsten M., Halperin Donna, Ahmed Sofia B., MacDonald Shannon E., Straus Sharon E., Manca Terra, Kamstra Josh Ng, Soo Andrea, Longmore Shelly, Kupsch Shelly, Sept Bonnie, Halperin Scott
Abstract
Abstract
Objective
COVID-19 transmission, emergence of variants of concern, and weakened immunity have led to recommended vaccine booster doses for COVID-19. Vaccine hesitancy challenges broad immunization coverage. We deployed a cross-national survey to investigate knowledge, beliefs, and behaviours toward continued COVID-19 vaccination.
Methods
We administered a national, cross-sectional online survey among adults in Canada between March 16 and March 26, 2022. We utilized descriptive statistics to summarize our sample, and tested for demographic differences, perceptions of vaccine effectiveness, recommended doses, and trust in decisions, using the Rao-Scott correction for weighted chi-squared tests. Multivariable logistic regression was adjusted for relevant covariates to identify sociodemographic factors and beliefs associated with vaccine hesitancy.
Results
We collected 2202 completed questionnaires. Lower education status (high school: odds ratio (OR) 1.90, 95% confidence interval (CI) 1.29, 2.81) and having children (OR 1.89, CI 1.39, 2.57) were associated with increased odds of experiencing hesitancy toward a booster dose, while higher income ($100,000–$149,999: OR 0.60, CI 0.39, 0.91; $150,000 or more: OR 0.49, CI 0.29, 0.82) was associated with decreased odds. Disbelief in vaccine effectiveness (against infection: OR 3.69, CI 1.98, 6.90; serious illness: OR 3.15, CI 1.69, 5.86), disagreeing with government decision-making (somewhat disagree: OR 2.70, CI 1.38, 5.29; strongly disagree: OR 4.62, CI 2.20, 9.7), and beliefs in over-vaccinating (OR 2.07, CI 1.53, 2.80) were found associated with booster dose hesitancy.
Conclusion
COVID-19 vaccine hesitancy may develop or increase regarding subsequent vaccines. Our findings indicate factors to consider when targeting vaccine-hesitant populations.
Funder
Canadian Institutes of Health Research
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,General Medicine
Reference30 articles.
1. Abraham, C., & Sheeran, P. (2014). The health belief model. Health and Medicine, 97–102. https://doi.org/10.1017/CBO9780511543579.022 2. Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., et al. (2021). Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. New England Journal of Medicine, 385(15), 1393–1400. https://doi.org/10.1056/NEJMoa2114255 3. Burns, K. E., Duffett, M., Kho, M. E., Meade, M. O., Adhikari, N. K., Sinuff, T., et al. (2008). A guide for the design and conduct of self-administered surveys of clinicians. CMAJ, 179(3), 245–252. https://doi.org/10.1503/cmaj.080372 4. Cénat, J. M., Noorishad, P. G., Moshirian Farahi, S. M. M., Darius, W. P., Mesbahi El Aouame, A., Onesi, O., et al. (2023). Prevalence and factors related to COVID-19 vaccine hesitancy and unwillingness in Canada: A systematic review and meta-analysis. Journal of Medical Virology, 95(1), e28156. https://doi.org/10.1002/jmv.28156 5. Centers for Disease Control and Prevention. (2023). COVID-19 Vaccinations in the United States. Atlanta, GA: US: Department of Health and Human Services, CDC.
|
|